Andrew M Scott Selected Research

fluoromisonidazole

1/2020	Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse.
1/2016	Fluorine-18 radiolabeling of a nitrophenyl sulfoxide and its evaluation in an SK-RC-52 model of tumor hypoxia.
5/2014	Radiolabelling and evaluation of a novel sulfoxide as a PET imaging agent for tumor hypoxia.
11/2013	Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
8/2012	Radiolabelling and evaluation of novel haloethylsulfoxides as PET imaging agents for tumor hypoxia.
11/2007	Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole.
12/2006	Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
3/2006	Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
12/2005	Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent.
9/2005	Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew M Scott Research Topics

Disease

135	Neoplasms (Cancer) 03/2022 - 02/2002
19	Glioblastoma (Glioblastoma Multiforme) 03/2021 - 05/2009
18	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2004
18	Hypoxia (Hypoxemia) 01/2020 - 02/2002
17	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 07/2005
14	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 07/2005
13	Glioma (Gliomas) 09/2011 - 02/2002
10	Renal Cell Carcinoma (Grawitz Tumor) 07/2018 - 05/2002
10	Carcinoma (Carcinomatosis) 01/2018 - 08/2003
8	Melanoma (Melanoma, Malignant) 01/2021 - 10/2002
6	Breast Neoplasms (Breast Cancer) 01/2021 - 08/2003
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 06/2004
4	Brain Neoplasms (Brain Tumor) 01/2021 - 02/2002
4	Disease Progression 01/2021 - 06/2010
4	Malignant Mesothelioma 12/2020 - 06/2011
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2015 - 02/2007
4	Lung Neoplasms (Lung Cancer) 06/2009 - 06/2004
3	Mesothelioma 10/2020 - 06/2011
3	Ischemic Stroke 01/2018 - 08/2012
2	Hematologic Neoplasms (Hematological Malignancy) 03/2022 - 10/2017
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2022 - 03/2009
2	Lymphoma (Lymphomas) 02/2022 - 03/2012
2	Hypertension (High Blood Pressure) 01/2022 - 02/2009
2	Oncogene Addiction 01/2020 - 05/2009

Drug/Important Bio-Agent (IBA)

38	Monoclonal AntibodiesIBA 10/2020 - 03/2002
32	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2003
31	AntibodiesIBA 03/2022 - 03/2002
30	AntigensIBA 01/2021 - 05/2002
22	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2002
18	epidermal growth factor receptor VIIIIBA 03/2021 - 03/2002
15	Immunoconjugates (Immunoconjugate)IBA 03/2022 - 11/2009
13	monoclonal antibody 806IBA 05/2015 - 03/2002
12	LigandsIBA 01/2021 - 08/2004
12	fluoromisonidazoleIBA 01/2020 - 02/2002
10	EpitopesIBA 10/2020 - 07/2004
9	Biological ProductsIBA 10/2015 - 08/2005
7	Radioisotopes (Radionuclides)IBA 03/2022 - 02/2007
7	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022 - 03/2006
7	depatuxizumab mafodotinIBA 01/2021 - 12/2017
7	Tyrosine Kinase InhibitorsIBA 01/2018 - 10/2005
7	Glucose (Dextrose)FDA LinkGeneric 07/2012 - 06/2004
6	Pharmaceutical PreparationsIBA 01/2021 - 10/2015
6	Eph Family Receptors (Eph Receptors)IBA 01/2021 - 02/2012
6	CarbohydratesIBA 10/2015 - 07/2004
6	Hu3S193 monoclonal antibodyIBA 08/2015 - 08/2003
5	EphrinsIBA 01/2022 - 08/2005
5	EnzymesIBA 01/2021 - 12/2006
5	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 12/2003
5	CytokinesIBA 09/2019 - 05/2002
5	VaccinesIBA 01/2017 - 07/2004
5	Phosphotransferases (Kinase)IBA 12/2014 - 02/2007
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2018
4	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 01/2016
4	depatuxizumabIBA 01/2021 - 05/2015
4	Cetuximab (Erbitux)FDA Link 11/2015 - 02/2007
4	Therapeutic UsesIBA 11/2015 - 02/2007
4	Blood Group Antigens (Blood Groups)IBA 10/2015 - 07/2004
4	Lewis Y antigenIBA 08/2015 - 06/2007
4	PolymersIBA 08/2012 - 09/2007
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 11/2015
3	LipidsIBA 01/2021 - 11/2019
3	AndrogensIBA 01/2021 - 06/2009
3	ABT-414IBA 10/2020 - 07/2017
3	Cytotoxins (Cytolysins)IBA 01/2019 - 12/2005
3	Platelet-Derived Growth FactorIBA 01/2018 - 01/2018
3	platelet-derived growth factor C (PDGF-C)IBA 01/2018 - 01/2018
3	Epidermal Growth Factor (EGF)IBA 01/2016 - 06/2009
3	SulfoxidesIBA 01/2016 - 08/2012
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2016 - 12/2003
3	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2016 - 11/2013
3	DisulfidesIBA 01/2016 - 09/2011
3	Serine Proteases (Serine Protease)IBA 11/2015 - 11/2012
3	Immunoglobulin G (IgG)IBA 08/2015 - 08/2008
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2015 - 04/2006
3	Tyrosine (L-Tyrosine)FDA Link 12/2014 - 06/2009
3	Carbonic Anhydrase IXIBA 07/2011 - 07/2009
3	Interleukin-2 (IL2)IBA 08/2007 - 05/2002
2	Capecitabine (Xeloda)FDA Link 01/2022 - 04/2014
2	Bevacizumab (Avastin)FDA Link 01/2022 - 11/2015
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2021 - 12/2020
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2020
2	Fluorine-18IBA 01/2021 - 06/2004
2	Messenger RNA (mRNA)IBA 01/2021 - 12/2006
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021 - 01/2021
2	fluoromethylcholineIBA 01/2021 - 01/2019
2	RadiopharmaceuticalsIBA 01/2021 - 01/2021
2	Lutetium-177IBA 01/2021 - 01/2009
2	Everolimus FDA Link 01/2020 - 01/2017
2	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2019 - 12/2015
2	monomethyl auristatin EIBA 01/2019 - 01/2018
2	IntegrinsIBA 01/2019 - 06/2015
2	gallium 68 PSMA-11IBA 01/2019 - 01/2018

Therapy/Procedure

70	Therapeutics 03/2022 - 03/2002
18	Drug Therapy (Chemotherapy) 01/2022 - 09/2005
14	Radiotherapy 02/2022 - 09/2005
10	Immunotherapy 01/2021 - 05/2002
10	Radioimmunotherapy 12/2016 - 07/2005
4	Precision Medicine 03/2022 - 01/2019
3	Castration 01/2021 - 10/2018
3	Prostatectomy (Retropubic Prostatectomy) 01/2019 - 05/2011